Search Results
268 items found for "drug combination"
- Location bias contributes to functionally selective responses of biased CXCR3 agonists
is critical to the overall biased response observed at CXCR3, which has important implications for drugs
- G-protein-coupled receptors as therapeutic targets for glioblastoma
receptor-4 (MC4R), adhesion, lysophosphatidic acid (LPA) and smoothened (Smo) receptors to initiate new drug-screening
- Fluorescent Ligands Targeting Intracellular Allosteric Binding Site of the Chemokine Receptor CCR2
binding site (IABS) of the CC chemokine receptor 2 (CCR2), a class A GPCR that has been pursued as a drug
- Dopamine D 1 receptor-mediated β-arrestin signaling: Insight from pharmacology, biology, behavior...
selectivity/biased signaling has led to the discovery of biased compounds as both research tools and novel drugs
- Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline ...
Develop AI-driven Pipeline of Precision-Engineered Medicines "Collaborative efforts aim to accelerate drug
- 📰 GPCR Weekly News, May 1 to 7, 2023
GPCR Binders, Drugs, and more Adenylyl cyclase 6 plays a minor role in the mouse inner ear and retina Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.
- Ligands can differentially and temporally modulate GPCR interaction with 14-3-3 isoforms
certain GPCR ligands can regulate GPCR/14-3-3 signals temporally, suggesting a new approach for GPCR drug
- Functional modulation of PTH1R activation and signaling by RAMP2
of a GPCR that may provide a new venue for highly specific modulation of GPCR function and advanced drug
- Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
), machine learning, and the design of protein structures in the discovery and development of novel drug
- OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet ...
Her work in the field has been instrumental and is set to shape the future of drug discovery for years
- Cholesterol-Dependent Dynamics of the Serotonin 1A Receptor Utilizing Single Particle Tracking....
signaling hubs in cell membranes that regulate a wide range of physiological processes and are popular drug
- Addex Raises $10 Million In Equity Financing
ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug
- Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain " — Confo’s first drug
- From DNA day to GPCR genomics
sparked a new era of a comprehensive understanding of GPCR biology, the development of GPCR-targeted drugs Furthermore, computational genomics approaches, such as structural bioinformatics analysis, have facilitated drug
- Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone...
findings regarding the complex biology of the preproglucagon-derived hormones, their signaling, and the drug
- Mechanistic Understanding of the Palmitoylation of Go Protein in the Allosteric Regulation of...
regulation of aGPCRs via post-translational modifications of the Go protein, and offers guidance for future drug
- Cholesterol-Dependent Dynamics of the Serotonin1A Receptor Utilizing Single Particle Tracking: ...
signaling hubs in cell membranes that regulate a wide range of physiological processes and are popular drug
- 📰 GPCR Weekly News, March 11 to 17, 2024
Terry Kenakin's "Applying Pharmacology to Drug Discovery" course at Dr. 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug
- GPR84 signaling promotes intestinal mucosal inflammation via enhancing NLRP3 inflammasome activation
in innate immune cells and intestinal inflammation, and suggest that GPR84 may serve as a potential drug
- Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...
ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug
- Addex raises $4.2 million in equity financing
ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug
- G protein-coupled receptors that influence lifespan of human and animal models
We also discuss the possibility of using agonist or antagonist drugs, depending on the beneficial or
- In vitro assays for the functional characterization of (psychedelic) substances at the serotonin...
Besides their appearance on the (illicit) drug market, e.g. as new psychoactive substances, their potential
- 📰 GPCR Weekly News, May 27 to June 2, 2024
Engineering G protein-coupled receptors for stabilization Cryo-electron microscopy for GPCR research and drug June 4, 2024 | Live Webinar ‘It All Starts With a Protein – Protein Sciences as a Key to Success in Drug
- A2B Adenosine Receptor Enhances Chemoresistance of Glioblastoma Stem-Like Cells under Hypoxia: New..
chemoresistance of GSCs is mediated in part by adenosine signaling and ABC transporters, which extrude drugs
- APEX2/AUR Biosensor: A Powerful Tool for Protein Interaction and Trafficking
development of molecular tools to study GPCR trafficking in real-time opens new avenues for understanding drug
- 📰 GPCR Weekly News, April 15 to 21, 2024
agonist-driven regulation of the neurokinin 1 receptor using a GPCR phosphorylation immunoassay GPCR Binders, Drugs the treatment of cannabis use disorder Orion Biotechnology will be presenting at the 19th Biopharma Drug
- Crinetics Pharmaceuticals announced the formation of an independently operated new company...
Provided by 5AM and Frazier – Pipeline is Built from Crinetics’ Core Nonpeptide Platform and Includes Drug